Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
6.44
+0.01 (0.16%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Minerva Neurosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -293.42 | 1.44 | -30.01 | -32.11 | -49.91 | |
| Depreciation & Amortization | 0.01 | 0.01 | 0.01 | - | 0.1 | |
| Other Amortization | - | 0.02 | 0.03 | 0.01 | - | |
| Asset Writedown & Restructuring Costs | - | - | - | - | 15.2 | |
| Stock-Based Compensation | 1.33 | 1.33 | 1.97 | 4.11 | 5.22 | |
| Other Operating Activities | 279.21 | -22.02 | 8.28 | 7.41 | 4.52 | |
| Change in Accounts Payable | -1.06 | -0.2 | 0.84 | -0.88 | 0.86 | |
| Change in Other Net Operating Assets | 0.43 | -0.12 | 4.1 | -3.18 | -0.6 | |
| Operating Cash Flow | -13.51 | -19.55 | -14.78 | -24.65 | -24.6 | |
| Capital Expenditures | - | - | - | -0.02 | - | |
| Investing Cash Flow | - | - | - | -0.02 | - | |
| Issuance of Common Stock | 80 | - | 20 | - | - | |
| Other Financing Activities | -5.55 | - | -0.4 | -0 | 60 | |
| Financing Cash Flow | 74.45 | - | 19.6 | -0 | 60 | |
| Net Cash Flow | 60.94 | -19.55 | 4.82 | -24.66 | 35.4 | |
| Free Cash Flow | -13.51 | -19.55 | -14.78 | -24.66 | -24.6 | |
| Free Cash Flow Per Share | -1.60 | -2.58 | -2.27 | -4.62 | -4.61 | |
| Levered Free Cash Flow | -8.54 | -15.48 | -12.69 | -20.36 | -17.08 | |
| Unlevered Free Cash Flow | -8.54 | -12.63 | -7.51 | -15.73 | -13.13 | |
| Change in Working Capital | -0.63 | -0.32 | 4.94 | -4.06 | 0.26 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.